Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
Acquired by Alexion Pharmaceuticals
|
| gptkbp:clinical_trial |
Phase 3 trials
|
| gptkbp:focus_area |
Immunology
Blood disorders Thrombosis |
| gptkbp:founded |
gptkb:2003
|
| gptkbp:founder |
William Lis
|
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Portola Pharmaceuticals
|
| gptkbp:key_people |
gptkb:Michael_A._Mc_Gowan
Charles B. Mc Cauley |
| gptkbp:partnerships |
Various biopharmaceutical companies
|
| gptkbp:products |
gptkb:Andexxa
gptkb:Cerdulatinib |
| gptkbp:stock_symbol |
PTLA
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.portola.com
|
| gptkbp:bfsParent |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|